From Zacks Investment Research: 2025-01-20 16:24:09

Johnson & Johnson (JNJ) is set to report its Q4 earnings on Jan. 22, with sales estimated at $22.5 billion and earnings at $2.01 per share. JNJ has exceeded earnings expectations the past four quarters. The stock has declined 9.5% in the past year. Sales in the Innovative Medicines segment are expected to be driven by key products like Darzalex and Tremfya. JNJ’s diversified business model and recent acquisitions are positive indicators. Despite legal issues and patent expirations, JNJ’s outlook for 2025 looks positive, making it a good long-term investment option.



Read more at Zacks Investment Research: Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Earnings? – January 20, 2025